ASCO Annual Meeting: Sarcoma | Conference

Sylvie Bonvalot, MD, PhD, Discusses Selecting Patients With Locally Advanced Sarcoma for Pre and Postoperative Treatment
August 06, 2021

CancerNetwork® sat down with Sylvie Bonvalot, MD, PhD, at the 2021 ASCO Annual Meeting to talk about treatment options for high-grade or grade II sarcoma.

Pimitespib Improved PFS Compared to Placebo for Advanced Refractory GIST
June 08, 2021

Pimitespib significantly improved progression-free survival while prolonging overall survival compared with placebo to treat patients with advanced gastrointestinal stromal tumor.

Benefit Observed With Catequentinib to Treat Advanced Synovial Sarcoma
June 05, 2021

Patients with advanced synovial sarcoma who received treatment with catequentinib experienced improved disease control and progression-free survival compared with dacarbazine.

Synovial Sarcoma Sees Impressive Responses With T-Cell Therapy Afamitresgene Autoleucel
June 05, 2021

Results of the phase 2 SPEARHEAD-1 trial were presented at the 2021 ASCO Annual Meeting, with a high overall response rate reported with afamitresgene autoleucel in advanced synovial sarcoma or myxoid/round cell liposarcoma.

Kelly Morgan, MS, CGC, on Improving Family Discussions on Genetic Risk for Cancer
August 14, 2020

The MSK expert explained that pre- and post-test education on genetic testing also improved family discussions about their risk.

Anlotinib Offers Efficacy Across Subtypes of Soft-Tissue Sarcoma
June 13, 2016

A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.

Gemcitabine Plus Pazopanib Shows Promise in Soft-Tissue Sarcomas
June 07, 2016

Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.

Quality of Life Could Help Select Treatment for Soft-Tissue Sarcoma
June 07, 2016

Understanding quality of life and the detrimental impact of disease progression is critical for long-term care and survival of patients with soft-tissue sarcoma.

Busulfan/Melphalan Associated With Longer Survival in High-Risk Ewing Sarcoma
June 06, 2016

Busulfan/melphalan high-dose chemotherapy consolidation is associated with better survival vs VAI among patients with localized high-risk Ewing sarcoma.

Regorafenib Ups Progression-Free Survival in Several Soft-Tissue Sarcomas
June 06, 2016

Regorafenib is associated with improved progression-free survival in pretreated patients with advanced refractory non-liposarcoma soft-tissue sarcomas.